Abiopharma

KKR Announces Intra-Quarter Update

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10)Advanced Triple-Negative Breast Cancer (TNBC)

Jacobs named supplier on UK government construction professional services framework

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

CMC Reports Third Quarter of Fiscal 2026 Results

Results of the general meeting dated 25.6.26

Share Buy Back - Daily Share Buy-Back Notice: Daily Share Buy-Back Notice

General Announcement: Reporting Share Repurchase form for Financial Management Purposes No.2

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement